Cargando…
Retrospective National “Real Life” Experience of the SFCE with the Metronomic MEMMAT and MEMMAT-like Protocol
Background: Relapses in pediatric high-risk brain tumors remain unmet medical needs. Over the last 15 years, metronomic chemotherapy has gradually emerged as an alternative therapeutic approach. Patients and Methods: This is a national retrospective study of patients with relapsing pediatric brain t...
Autores principales: | , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9967517/ https://www.ncbi.nlm.nih.gov/pubmed/36835950 http://dx.doi.org/10.3390/jcm12041415 |
_version_ | 1784897284371120128 |
---|---|
author | Winnicki, Camille Leblond, Pierre Bourdeaut, Franck Pagnier, Anne Paluenzela, Gilles Chastagner, Pascal Duhil-De Benaze, Gwenaelle Min, Victoria Sudour-Bonnange, Hélène Piette, Catherine Entz-Werle, Natacha Chabaud, Sylvie André, Nicolas |
author_facet | Winnicki, Camille Leblond, Pierre Bourdeaut, Franck Pagnier, Anne Paluenzela, Gilles Chastagner, Pascal Duhil-De Benaze, Gwenaelle Min, Victoria Sudour-Bonnange, Hélène Piette, Catherine Entz-Werle, Natacha Chabaud, Sylvie André, Nicolas |
author_sort | Winnicki, Camille |
collection | PubMed |
description | Background: Relapses in pediatric high-risk brain tumors remain unmet medical needs. Over the last 15 years, metronomic chemotherapy has gradually emerged as an alternative therapeutic approach. Patients and Methods: This is a national retrospective study of patients with relapsing pediatric brain tumors treated according to the MEMMAT or MEMMAT-like regimen from 2010 to 2022. Treatment consisted of daily oral thalidomide, fenofibrate, and celecoxib, and alternating 21-day cycles of metronomic etoposide and cyclophosphamide associated with bevacizumab and intraventricular chemotherapy. Results: Forty-one patients were included. The most frequent malignancies were medulloblastoma (22) and ATRT (8). Overall, the best responses were CR in eight patients (20%), PR in three patients (7%), and SD in three patients (7%), for a clinical benefit rate of 34%. The median overall survival was 26 months (IC95% = 12.4–42.7), and median EFS was 9.7 months (IC95% = 6.0–18.6). The most frequent grade ¾ toxicities were hematological. Dose had to be adjusted in 27% of the cases. There was no statistical difference in outcome between full or modified MEMMAT. The best setting seems to be when MEMMAT is used as a maintenance and at first relapse. Conclusions: The metronomic MEMMAT combination can lead to sustained control of relapsed high-risk pediatric brain tumors. |
format | Online Article Text |
id | pubmed-9967517 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-99675172023-02-27 Retrospective National “Real Life” Experience of the SFCE with the Metronomic MEMMAT and MEMMAT-like Protocol Winnicki, Camille Leblond, Pierre Bourdeaut, Franck Pagnier, Anne Paluenzela, Gilles Chastagner, Pascal Duhil-De Benaze, Gwenaelle Min, Victoria Sudour-Bonnange, Hélène Piette, Catherine Entz-Werle, Natacha Chabaud, Sylvie André, Nicolas J Clin Med Article Background: Relapses in pediatric high-risk brain tumors remain unmet medical needs. Over the last 15 years, metronomic chemotherapy has gradually emerged as an alternative therapeutic approach. Patients and Methods: This is a national retrospective study of patients with relapsing pediatric brain tumors treated according to the MEMMAT or MEMMAT-like regimen from 2010 to 2022. Treatment consisted of daily oral thalidomide, fenofibrate, and celecoxib, and alternating 21-day cycles of metronomic etoposide and cyclophosphamide associated with bevacizumab and intraventricular chemotherapy. Results: Forty-one patients were included. The most frequent malignancies were medulloblastoma (22) and ATRT (8). Overall, the best responses were CR in eight patients (20%), PR in three patients (7%), and SD in three patients (7%), for a clinical benefit rate of 34%. The median overall survival was 26 months (IC95% = 12.4–42.7), and median EFS was 9.7 months (IC95% = 6.0–18.6). The most frequent grade ¾ toxicities were hematological. Dose had to be adjusted in 27% of the cases. There was no statistical difference in outcome between full or modified MEMMAT. The best setting seems to be when MEMMAT is used as a maintenance and at first relapse. Conclusions: The metronomic MEMMAT combination can lead to sustained control of relapsed high-risk pediatric brain tumors. MDPI 2023-02-10 /pmc/articles/PMC9967517/ /pubmed/36835950 http://dx.doi.org/10.3390/jcm12041415 Text en © 2023 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Article Winnicki, Camille Leblond, Pierre Bourdeaut, Franck Pagnier, Anne Paluenzela, Gilles Chastagner, Pascal Duhil-De Benaze, Gwenaelle Min, Victoria Sudour-Bonnange, Hélène Piette, Catherine Entz-Werle, Natacha Chabaud, Sylvie André, Nicolas Retrospective National “Real Life” Experience of the SFCE with the Metronomic MEMMAT and MEMMAT-like Protocol |
title | Retrospective National “Real Life” Experience of the SFCE with the Metronomic MEMMAT and MEMMAT-like Protocol |
title_full | Retrospective National “Real Life” Experience of the SFCE with the Metronomic MEMMAT and MEMMAT-like Protocol |
title_fullStr | Retrospective National “Real Life” Experience of the SFCE with the Metronomic MEMMAT and MEMMAT-like Protocol |
title_full_unstemmed | Retrospective National “Real Life” Experience of the SFCE with the Metronomic MEMMAT and MEMMAT-like Protocol |
title_short | Retrospective National “Real Life” Experience of the SFCE with the Metronomic MEMMAT and MEMMAT-like Protocol |
title_sort | retrospective national “real life” experience of the sfce with the metronomic memmat and memmat-like protocol |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9967517/ https://www.ncbi.nlm.nih.gov/pubmed/36835950 http://dx.doi.org/10.3390/jcm12041415 |
work_keys_str_mv | AT winnickicamille retrospectivenationalreallifeexperienceofthesfcewiththemetronomicmemmatandmemmatlikeprotocol AT leblondpierre retrospectivenationalreallifeexperienceofthesfcewiththemetronomicmemmatandmemmatlikeprotocol AT bourdeautfranck retrospectivenationalreallifeexperienceofthesfcewiththemetronomicmemmatandmemmatlikeprotocol AT pagnieranne retrospectivenationalreallifeexperienceofthesfcewiththemetronomicmemmatandmemmatlikeprotocol AT paluenzelagilles retrospectivenationalreallifeexperienceofthesfcewiththemetronomicmemmatandmemmatlikeprotocol AT chastagnerpascal retrospectivenationalreallifeexperienceofthesfcewiththemetronomicmemmatandmemmatlikeprotocol AT duhildebenazegwenaelle retrospectivenationalreallifeexperienceofthesfcewiththemetronomicmemmatandmemmatlikeprotocol AT minvictoria retrospectivenationalreallifeexperienceofthesfcewiththemetronomicmemmatandmemmatlikeprotocol AT sudourbonnangehelene retrospectivenationalreallifeexperienceofthesfcewiththemetronomicmemmatandmemmatlikeprotocol AT piettecatherine retrospectivenationalreallifeexperienceofthesfcewiththemetronomicmemmatandmemmatlikeprotocol AT entzwerlenatacha retrospectivenationalreallifeexperienceofthesfcewiththemetronomicmemmatandmemmatlikeprotocol AT chabaudsylvie retrospectivenationalreallifeexperienceofthesfcewiththemetronomicmemmatandmemmatlikeprotocol AT andrenicolas retrospectivenationalreallifeexperienceofthesfcewiththemetronomicmemmatandmemmatlikeprotocol |